[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582506":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":28,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Imperial College London","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"participants with liver cancer",null,"Histologically or radiologically-confirmed hepatocellular carcinoma or cholangiocarcinoma",{"label":13,"type":10,"description":14,"interventionNames":10},"participants with benign liver disorders","1. Liver cirrhosis, confirmed on imaging or histology from biopsy or\n2. Primary sclerosing cholangitis, confirmed on MRCP\u002FERCP or histology from biopsy",{"label":16,"type":10,"description":17,"interventionNames":10},"healthy controls","Non-specific gastrointestinal symptoms, but a radiologically-normal liver",[19],{"name":20,"affiliation":5,"role":21},"George Hanna","PRINCIPAL_INVESTIGATOR",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Georgios Karagiannidis, MBBS(Hon)","CONTACT","+02075943396","vocal-study@imperial.ac.uk",[29],{"facility":5,"status":30,"city":31,"state":10,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","London","United Kingdom","UK",{"type":35,"coordinates":36},"Point",[37,38],-0.12574,51.50853,{"lat":38,"lon":37},[41],{"name":42,"role":25,"phone":26,"phoneExt":10,"email":27},"Georgios Karagiannidis",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100582506","a-simple-breath-test-to-detect-liver-cancer-and-monitor-liver-conditions-100582506",false,"NCT06864195","A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions","Development of a Breath Test Using Volatile Organic Markers for Monitoring Cirrhosis and Detecting Primary Liver Tumours (VOCAL2)","VOCAL2","Inclusion Criteria:\n\n* Males and females\n* Adult participants ≥ 18 years old\n* Participants with either:\n\n  1. Histologically or radiologically-confirmed\\* hepatocellular carcinoma or cholangiocarcinoma (participants with liver cancer)\n  2. Liver cirrhosis, confirmed on imaging or histology from biopsy (participants with benign liver disorders)\n  3. Primary sclerosing cholangitis, confirmed on MRCP\u002FERCP or histology from biopsy (participants with benign liver disorders)\n  4. Non-specific gastrointestinal symptoms, but a radiologically-normal liver (healthy controls)\n\nExclusion Criteria:\n\n* Active infection, or receiving immunosuppressive medications, within the preceding eight weeks\n* History of another cancer within the previous five years\n* Previous liver resection\n* Already received chemotherapy, radiotherapy or surgery for their liver cancer\n* Comorbidities preventing breath collection\n* Pregnant women (checked verbally with participant).\n* Unable to provide informed written consent",true,"ALL","18 Years",{"count":57,"type":58},750,"ESTIMATED","OBSERVATIONAL","Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease.\n\nWho can take part?\n\nAdults aged 18 or older who:\n\nHave liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary sclerosing cholangitis, or Have tummy symptoms but a normal liver scan. What's involved?\n\nParticipants will:\n\nGive a breath sample after fasting for 6 hours. Answer a few health questions. Allow access to relevant medical records. The appointment lasts about 1 hour at an NHS hospital. Benefits \\& Risks\n\nThis research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants.\n\nThere are no risks, as breath sampling is completely non-invasive and safe. Where is the study happening? Led by Imperial College London, running in NHS hospitals across the UK.\n\nWho is funding the study? The study is funded by Rosetrees and Stoneygate Trust.\n\nContact Information Email: vocal-study@imperial.ac.uk Phone: +44 (0)20 7594 3396",[62,63,64,65],"Liver Cirrhosis","Hepatocellular Carcinoma (HCC)","Cholangiocarcinoma","Cholangitis, Sclerosing",[67,68,69],"breath","liver cancer","cirrhosis","2025-03-03",{"date":72,"type":73},"2025-03-07","ACTUAL",{"date":75,"type":73},"2025-02-13",{"date":77,"type":58},"2027-02-28",{"name":5,"class":6},1]